Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838625 · ClinicalTrials.gov registry record · Phase 3
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Click Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 464
- Enrollment target
NCT05838625 is a Phase 3 study that has completed, run by Click Therapeutics. The registered enrollment target is 464 participants.
The verdict
NCT05838625, a Phase 3 study, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 464 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
Interventions
- DEVICE Digital Control
- DEVICE CT-155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2025-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05838625
The ClinicalTrials.gov registry entry for NCT05838625 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Click Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Digital Control is the first listed.
NCT05838625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05838625 about?
NCT05838625 is a clinical study titled "Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia". This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
What is the current status of trial NCT05838625?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 464 participants. The study started on 2023-03-31. Estimated completion is 2025-07-23.
What interventions are being tested in trial NCT05838625?
The interventions under investigation include: Digital Control (DEVICE), CT-155 (DEVICE).
Who is sponsoring clinical trial NCT05838625?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.